Description: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Home Page: www.pfizer.com
235 East 42nd Street
New York,
NY
10017
United States
Phone:
212 733 2323
Officers
| Name | Title |
|---|---|
| Dr. Albert Bourla D.V.M., DVM, Ph.D. | Chairman & CEO |
| Mr. Frank A. D'Amelio | CFO & Exec. VP |
| Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical |
| Mr. Douglas M. Lankler | Exec. VP & Gen. Counsel |
| Mr. John D. Young | Advisor |
| Ms. Angela Hwang | Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus. |
| Mr. David M. Denton | Chief Financial Officer & Exec. VP |
| Ms. Jennifer B. Damico | Sr. VP, Controller & Principal Accounting Officer |
| Ms. Lidia L. Fonseca | Exec. VP and Chief Digital & Technology Officer |
| Mr. Christopher J. Stevo CFA | Sr. VP & Chief Investor Relations Officer |
Exchange: SA
Country: BR
Currency: Brazilian real (R$)
| Forward PE: | 10.9409 |
|---|---|
| Trailing PE: | 9.0386 |
| Price-to-Book MRQ: | 3.2951 |
| Price-to-Sales TTM: | 15.4289 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 79000 |